Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L2-01 adipose-derived mesenchymal stem cells
- Development stage
- Phase 2
- Lead developer
- L2 Bio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
L2-01 adipose-derived mesenchymal stem cells are autologous or first-degree blood relative sourced adipose-derived mesenchymal stem cells (AD-MSCs) developed by L2 Bio. The product consists of stem cells harvested from a patient’s own adipose tissue or a close relative, processed and expanded ex vivo, and delivered intravenously. These cells are used for their immunomodulatory and anti-inflammatory properties, particularly for the treatment of Crohn’s Disease. The therapy is notable for its potentially high safety profile, very low risk of rejection, and personalized HLA/DNA matching when using autologous or relative donor tissue. L2 Bio has received FDA approval to conduct a Phase 2B clinical trial in Crohn’s Disease. The cells function by reducing inflammatory responses and inducing regulatory T cells, likely through the secretion of soluble factors such as IL-10, TGF-β, PGE2, and others. L2 Bio is leading the clinical development and banking of these ADSCs for therapeutic use[1][2][4].
- Other names
- L2-01 adipose-derived mesenchymal stem cellsL-2-01 adipose-derived mesenchymal stem cellsL 2-01 adipose-derived mesenchymal stem cellsL2-01 AD-MSCsL-2-01 AD-MSCsL 2-01 AD-MSCsL2 Bio adipose-derived mesenchymal stem cellsL-2 Bio adipose-derived mesenchymal stem cellsL 2 Bio adipose-derived mesenchymal stem cells
Beyond the preview
Go deeper on L2-01 adipose-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L2-01 adipose-derived mesenchymal stem cells.